Belgian KCE published a report on the evidence gaps at market entry in Europe for drugs and medical devices

27

Jan 2022

On December 17, 2021, the Belgian Health Care Knowledge Center (KCE) published a health services research report “Evidence gaps for drugs and medical devices at market entry in Europe and potential solutions”. In this report, KCE examined the lack of comparative evidence health technology assessment (HTA) agencies and payers face in evaluating new medicinal products and high-risk medical devices at market entry.

This project attempted to clarify the evidence requirements and the evidence gaps from various perspectives and with the aid of various information sources. For every source, a specific methodology was followed that was explained in the relevant chapters. The report includes the following data: an overview of the legal framework concerning the evidence requirements for putting high-risk medical devices and medicinal products on the European market; a brief overview of the evidence gaps reported by the National Institute for Health and Disability Insurance (INAMI/RIZIV) in the evaluation dossiers of medical devices or medicinal products; a literature study of the evidence gaps for high-risk medical devices and medicinal products; discussion of possible solutions.

A consultation with the group of experts in the field of medicinal products or high-risk medical devices from selected public HTA/payment institutes in Austria, Belgium, France, Germany, Ireland, Norway, the Netherlands, and the UK was performed. A similar consultation was also conducted with a group of experts in the field of legislation, ethics, and regulation and a group of physicians. The report provides a number of recommendations for different stakeholders to complete the lacking evidence and to avoid the evidence gaps in the future.

See the details in English here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more

10

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more